CGEM
Cullinan Therapeutics, Inc. NASDAQ Listed Jan 8, 2021$15.03
+4.09%
vs $14.44
Mkt Cap $887.5M
52w Low $5.75
86.8% of range
52w High $16.44
50d MA $14.43
200d MA $11.42
P/E (TTM)
—
EV/EBITDA
—
P/B
2.2x
Debt/Equity
0.0x
ROE
-53.8%
P/FCF
-5.0x
RSI (14)
40.80
ATR (14)
$1.19
Beta
-0.11
50d MA
$14.43
200d MA
$11.42
Avg Volume
1.3M
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
One Main Street · Cambridge, MA 02142 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 14.99 | +0.9% | -1.8% | -1.2% | +1.2% | +9.6% | +1.1% | — |
| Mar 10, 2026 | AMC | -0.80 | -0.77 | +3.8% | 14.91 | -1.6% | -4.0% | -2.5% | -3.3% | +4.0% | -4.2% | — |
| Nov 6, 2025 | AMC | -0.95 | -0.77 | +18.9% | 7.35 | -1.5% | -2.2% | +3.5% | +4.8% | +7.1% | -1.0% | — |
| Aug 7, 2025 | AMC | -0.83 | -1.07 | -28.9% | 7.03 | +0.1% | +3.8% | -2.9% | +2.5% | +5.1% | -0.8% | — |
| May 8, 2025 | AMC | -0.78 | -0.74 | +5.1% | 7.77 | -0.1% | -3.0% | +4.9% | -3.7% | -6.4% | +1.5% | — |
| Feb 27, 2025 | AMC | -0.75 | -0.73 | +2.7% | 8.61 | +0.5% | -1.4% | -5.8% | +1.6% | +3.7% | +0.9% | — |
| Nov 7, 2024 | AMC | -0.78 | -0.69 | +11.5% | 15.58 | +1.7% | +2.8% | +7.8% | -7.2% | -1.4% | -3.1% | — |
| Aug 8, 2024 | AMC | -0.73 | -0.75 | -2.7% | 16.38 | +3.2% | +2.4% | -2.8% | -0.1% | -0.3% | +4.1% | — |
| May 15, 2024 | AMC | -0.90 | -0.86 | +4.4% | 26.72 | +0.3% | -10.9% | -2.7% | +3.5% | -3.4% | -0.1% | — |
| Mar 14, 2024 | AMC | -0.96 | -0.54 | +43.8% | 16.91 | -0.2% | -5.8% | -3.8% | +1.2% | +0.2% | +5.2% | — |
| Nov 8, 2023 | AMC | -0.91 | -0.91 | +0.0% | 9.94 | +1.6% | -3.5% | -5.2% | -3.5% | +8.2% | -6.5% | — |
| Aug 10, 2023 | AMC | -0.99 | -0.82 | +17.2% | 10.29 | +0.5% | +5.1% | -5.0% | -0.6% | -1.9% | +0.6% | — |
| May 11, 2023 | AMC | -0.84 | -1.42 | -69.0% | 9.62 | -9.0% | +1.5% | +1.8% | -8.1% | -3.3% | -0.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.25 | $13.40 | +1.1% | -3.3% | +0.3% | +1.6% | +2.9% | +14.2% |
| Mar 11 | Wedbush | Maintains | Outperform → Outperform | — | $14.91 | $14.67 | -1.6% | -4.0% | -2.5% | -3.3% | +4.0% | -4.2% |
| Jan 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.94 | $10.71 | -2.1% | +1.8% | -2.2% | -2.7% | +1.1% | +1.3% |
| Dec 9 | Wedbush | Maintains | Outperform → Outperform | — | $12.44 | $12.44 | +0.0% | -0.6% | +0.8% | -0.6% | -3.7% | -9.2% |
| Nov 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.45 | $8.63 | +2.1% | +3.2% | +8.6% | +36.5% | -8.8% | -0.4% |
| Sep 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.62 | $6.57 | -0.8% | -1.4% | -2.8% | -0.9% | -5.7% | +6.9% |
| Sep 10 | BTIG | Maintains | Buy → Buy | — | $6.83 | $6.77 | -0.9% | -5.3% | +2.3% | -1.4% | -2.8% | -0.9% |
| Aug 18 | Morgan Stanley | Maintains | Overweight → Overweight | — | $7.66 | $7.64 | -0.3% | +3.8% | -4.7% | -1.5% | +2.7% | +6.8% |
| May 12 | UBS | Maintains | Buy → Buy | — | $7.54 | $7.93 | +5.2% | +4.9% | -3.7% | -6.4% | +1.5% | +3.6% |
| Apr 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.80 | $7.69 | -1.4% | -2.4% | +3.7% | +2.7% | +3.3% | +0.1% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.61 | $8.65 | +0.5% | -1.4% | -5.8% | +1.6% | +3.7% | +0.9% |
| Feb 28 | Stifel | Maintains | Buy → Buy | — | $8.61 | $8.65 | +0.5% | -1.4% | -5.8% | +1.6% | +3.7% | +0.9% |
| Aug 9 | Wedbush | Maintains | Outperform → Outperform | — | $16.38 | $16.90 | +3.2% | +2.4% | -2.8% | -0.1% | -0.3% | +4.1% |
| Jun 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.50 | $22.86 | -2.7% | -4.1% | -0.6% | +2.0% | -1.3% | -0.6% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.65 | $22.61 | -0.2% | +6.5% | -4.6% | -1.5% | +0.5% | +3.1% |
| May 16 | Wedbush | Maintains | Outperform → Outperform | — | $26.72 | $26.79 | +0.3% | -10.9% | -2.7% | +3.5% | -3.4% | -0.1% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.72 | $26.79 | +0.3% | -10.9% | -2.7% | +3.5% | -3.4% | -0.1% |
| Apr 17 | JonesTrading | Maintains | Buy → Buy | — | $17.32 | $18.01 | +4.0% | +3.2% | +1.0% | -13.3% | -0.2% | +6.7% |
| Apr 17 | BTIG | Maintains | Buy → Buy | — | $17.32 | $18.01 | +4.0% | +3.2% | +1.0% | -13.3% | -0.2% | +6.7% |
| Apr 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.55 | $19.87 | +20.1% | +4.7% | +3.2% | +1.0% | -13.3% | -0.2% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.98 | $16.79 | -1.1% | -0.4% | -5.8% | -3.8% | +1.2% | +0.2% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.29 | $10.34 | +0.5% | +5.1% | -5.0% | -0.6% | -1.9% | +0.6% |
| Jul 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.48 | $10.41 | -0.7% | -1.9% | -2.9% | +0.6% | +3.3% | +11.1% |
| Jun 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.53 | $10.63 | +0.9% | +10.6% | +5.5% | +9.1% | -3.0% | +0.8% |
| May 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.56 | $9.54 | -0.2% | +5.1% | +1.8% | +0.5% | -1.2% | +3.6% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.62 | $8.75 | -9.0% | +1.5% | +1.8% | -8.1% | -3.3% | -0.3% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.51 | $10.61 | +1.0% | +3.7% | -3.9% | +2.7% | -5.2% | +0.3% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.07 | $10.93 | -1.3% | -1.6% | +1.0% | +3.8% | -1.8% | -3.1% |
| Feb 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.38 | $11.26 | -1.1% | +1.5% | -4.2% | +2.5% | -3.1% | +0.4% |
| Feb 3 | Morgan Stanley | Maintains | Overweight → Overweight | — | $11.91 | $11.84 | -0.6% | -1.2% | -3.1% | +0.4% | +0.5% | -0.9% |
| Nov 21 | BTIG | Maintains | Buy → Buy | — | $12.41 | $13.10 | +5.6% | +2.8% | +3.4% | +1.6% | -1.0% | -5.4% |
| May 13 | SVB Leerink | Maintains | Outperform → Outperform | — | $9.00 | $9.33 | +3.7% | +18.0% | +2.4% | +10.8% | -5.6% | -5.0% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.81 | $12.55 | -2.0% | +4.1% | -3.8% | -1.6% | -4.5% | +1.4% |
| Jun 7 | Morgan Stanley | Maintains | Overweight → Overweight | — | $33.11 | $33.20 | +0.3% | +2.3% | -1.2% | -2.5% | -1.2% | -2.5% |
| Jun 4 | SVB Leerink | Maintains | Outperform → Outperform | — | $29.76 | $37.59 | +26.3% | +11.3% | +2.3% | -1.2% | -2.5% | -1.2% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.76 | $37.59 | +26.3% | +11.3% | +2.3% | -1.2% | -2.5% | -1.2% |
| Apr 27 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $31.68 | $33.70 | +6.4% | +9.4% | -4.2% | -1.3% | -1.0% | +5.5% |
| Apr 19 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $35.20 | $35.03 | -0.5% | -8.8% | -2.5% | +8.1% | -4.0% | -3.0% |
| Mar 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.05 | $38.02 | -0.1% | +4.4% | +4.9% | -1.0% | -0.6% | -14.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | Michaelson Jennifer | Chief Scientific Officer | Sell | 200 | $15.58 | $3K | 166,844 | -1.80% | +1.11% |
| May 5, 2026 | Michaelson Jennifer | Chief Scientific Officer | Sell | 7,800 | $14.60 | $114K | 167,044 | -1.80% | +1.11% |
8-K · 8.01
!! High
Cullinan Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 10
8-K · 8.01
!! High
Cullinan Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Cullinan Therapeutics disclosed positive Phase 1 OUTRACE trial data for CLN-978 across 29 rheumatoid arthritis and lupus patients, advancing its pipeline for treatment-resistant inflammatory diseases.
Jun 8
8-K · 2.02
!! High
Cullinan Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Cullinan Therapeutics reported Q1 2026 financial results, providing investors with updates on the company's operational performance and cash position during the first quarter.
May 7
8-K
Unknown — 8-K Filing
Cullinan Therapeutics has sufficient cash ($439M runway through 2029) to reach multiple clinical milestones in 2026, reducing near-term financing risk and supporting stock stability despite ongoing development timelines.
Mar 10
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Mpm Bioimpact Llc | 7,648,268 | $109M | — | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 2,483,034 | $35M | New | Mar 2026 |
| 3 | Blue Owl Capital Holdings Lp | 1,909,764 | $27M | Reduced | Mar 2026 |
| 4 | Rtw Investments, Lp | 1,705,960 | $24M | — | Mar 2026 |
| 5 | Morgan Stanley | 1,533,868 | $16M | Added | Dec 2025 |
| 6 | Marshall Wace, Llp | 1,049,581 | $15M | Added | Mar 2026 |
| 7 | Vr Adviser, Llc | 1,379,965 | $14M | — | Dec 2025 |
| 8 | Point72 Asset Management | 905,376 | $13M | Added | Mar 2026 |
| 9 | Nuveen, Llc | 805,700 | $11M | Added | Mar 2026 |
| 10 | Twin Focus Capital Partners, Llc | 595,489 | $8M | — | Mar 2026 |
| 11 | Vanguard Portfolio Management Llc | 552,553 | $8M | New | Mar 2026 |
| 12 | Two Sigma Investments, Lp | 522,047 | $7M | Added | Mar 2026 |
| 13 | Bank Of America Corp /de/ | 516,724 | $7M | Reduced | Mar 2026 |
| 14 | Northern Trust Corp | 449,258 | $6M | Added | Mar 2026 |
| 15 | Soleus Capital Management, L.p. | 410,200 | $6M | New | Mar 2026 |
| 16 | Deerfield Management Company, L.p. | 386,169 | $5M | — | Mar 2026 |
| 17 | Aqr Capital Management Llc | 360,874 | $5M | Added | Mar 2026 |
| 18 | Millennium Management | 346,582 | $5M | Reduced | Mar 2026 |
| 19 | Renaissance Technologies Llc | 324,111 | $5M | Reduced | Mar 2026 |
| 20 | Jpmorgan Chase & Co | 297,231 | $4M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$887.5M
Enterprise Value
$511.5M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.14x
P/B
2.17x
P/S
—
P/FCF
-5.05x
EV/EBITDA
—
Shares Out
59.0M
Financials (TTM)
Revenue
$0
Net Income
-$221.0M
EBITDA
-$220.7M
Free Cash Flow
-$175.8M
Op Cash Flow
-$175.8M
EPS Basic
$-3.72
EPS Diluted
$-3.75
EPS Forward
$-3.13
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$448.4M
Total Liab.
$39.6M
Total Equity
$408.7M
Cash
$377.9M
LT Debt
$1.9M
Book Value/Sh
$6.92
Debt/Equity
0.01x
Current Ratio
10.25
Quick Ratio
10.25
Returns & Growth
ROE
-53.8%
ROA
-49.0%
ROIC
-58.7%
Rev Growth YoY
+0.0%
EPS Growth YoY
-19.6%
Price Returns
2W
+1.8%
1M
+26.0%
3M
+6.1%
6M
+44.6%
12M
+90.1%
Technicals
52W High
$16.44
52W Low
$5.75
50d MA
$14.43
200d MA
$11.42
RSI (14)
40.80
ATR (14)
$1.19
Beta
-0.11
Avg Volume
1.3M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$31.14
High
$38.00
Low
$26.00
Median
$30.00
Data updated apr 25, 2026 12:58am
· Source: financialmodelingprep.com